Global Preimplantation Genetics Diagnosis (PGD) Market Report, published by Variant Market Research, forecast that the global market is expected to reach $140 Million by 2024 from $86 Million in 2016, growing at a CAGR of 6.2% from 2016 to 2024. By geography, North America and Asia-Pacific are expected to grow at a CAGR of 6.7% and 6.4%, respectively, during the forecast period.
"Preimplantation Genetics Diagnosis (PGD) Market (By Test Type: Gender Selection, Chromosomal Abnormalities, Single Gene Disorders, HLA Typing, Aneuploidy, X-Linked Diseases, And Others; By Geography: North America, Europe, Asia-Pacific and RoW) Global Scenario, Market Size, Outlook, Trend and Forecast, 2015-2024"
Some of the factors driving the growth of the global preimplantation genetics diagnosis (PGD) market are declining fertility rate, advancements in the field of genetic analysis, increasing occurrence of genetic disorders, rising demand of IVF treatments, and high possibility of genetic abnormalities in embryos with progressing maternal age. Factors such as stringent government regulations and social-economic concerns would limit the growth of the market. However, rising R&D and market expansion would provide market opportunities in the coming years.
Test type and geography are the major bifurcations in the global preimplantation genetics diagnosis (PGD) market. Test type is further categorized as gender selection, chromosomal abnormalities, single gene disorders, HLA typing, aneuploidy, X-linked diseases, and other test types. Among which, chromosomal abnormalities accounted the largest market share, whereas, other test types shall attain the fastest CAGR during the forecast period 2016–2024.
Geographically, global preimplantation genetics diagnosis (PGD) market is bifurcated into North America, Europe, Asia Pacific, and RoW. Europe and North America accounted the maximum market share in 2016, with 31.5% and 26.8% respectively. In terms of growth, North America would dominate with fastest CAGR during the forecast period, driven by, high awareness among people regarding availability of such treatment, increasing infertility rate, and rising investments by government organizations.
Major market players include Abbott Laboratories, Natera, Inc., PerkinElmer, Inc., Illumina, Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., Cooper Surgical, Inc., and Beijing Genomics Institute (BGI), among others.